1
|
Minard-Colin V, Aupérin A, Burke A, Alexander S, Moreno M, Buffardi S, Uyttebroeck A, Bollard C, Zsiros J, Csoka M, Kazanowska B, Chiang A, Verschuur A, Miles R, Wotherspoon A, Barkauskas D, Wheatley K, Vassal G, Adamson P, Gross T, Patte C, Pillon M. INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00255-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
2
|
Alexander S, Aupérin A, Bomken S, Csoka M, Kazanowska B, Chiang A, Moreno MA, Uyttebroeck A, Burke A, Zsiros J, Pillon M, Bollard C, Barkauskas D, Wheatley K, Patte C, Gross T, Minard-Colin V. IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL. Leuk Res 2022. [DOI: 10.1016/s0145-2126(22)00205-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
3
|
Bonan N, Chen J, Ghofrani J, Medina J, Bollard C, Yvon E, Fernandes R. Gene Editing/Gene Therapies: HUMAN ALLOGENEIC NK CELLS MODIFIED TO EXPRESS A TGF-β DOMINANT NEGATIVE RECEPTOR AND IL-15 DISPLAY A STRONG ANTI-TUMOR ACTIVITY IN AN NSG MOUSE MODEL OF HUMAN MESOTHELIOMA. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00152-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Motta C, Abraham A, Keller M, Bollard C. Immunotherapy: Late Breaking Abstract: GENERATION OF DONOR-DERIVED MULTI-VIRUS SPECIFIC T CELLS (VST) TARGETING CYTOMEGALOVIRUS (CMV), EPSTEIN-BARR VIRUS (EBV), ADENOVIRUS, BK VIRUS AND SARS-COV2 TO PREVENT VIRAL INFECTION IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AFTER BONE MARROW TRANSPLANT. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00360-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Chaudhry K, Geiger A, Dowlati E, Lang H, Yvon E, Holdoff M, Jones R, Savoldo B, Cruz C, Bollard C. Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00148-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
6
|
Geiger A, Stanojevic M, Hont A, Lazarski C, Datar A, Lang H, Hanley P, Bollard C, Nazarian J, Hwang E, Cruz C. Immunotherapy: DEVELOPING OFF THE SHELF T CELL THERAPIES FOR HIGH-GRADE GLIOMAS. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00308-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Srinivasan M, Val S, Ulrey R, Chonchoro H, Datar A, Bollard C, Kuo M, Peshwa M, Hanley P. 50+ fold scale-up in cGMP manufacture of multi-antigen reactive allogeneic T-cells to permit 25-fold higher dosing than the highest dose infused in prior human trials. Cytotherapy 2021. [DOI: 10.1016/s1465324921005594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Durkee-Shock J, Lazarski C, Jensen-Wachspress M, Kankate V, Lang H, Hanley P, Bollard C, Keller M. Cytokine optimization of SARS-CoV-2 specific T-cells for therapeutic use. Cytotherapy 2021. [DOI: 10.1016/s1465324921004369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Stanojevic M, O'Brien S, Geiger A, Ulrey R, Cruz C, Hanley P, Keller M, Bollard C. Identification of Novel HLA-Restricted PRAME Peptides to Facilitate “Off-the-shelf” Tumor-Associated Antigen-specific T-cells. Cytotherapy 2020. [DOI: 10.1016/j.jcyt.2020.03.269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
10
|
Lazarski C, Keller M, Bollard C, Hanley P. Designing a high throughput multi-parameter assay for process development of antigen specific T cell therapy products. Cytotherapy 2019. [DOI: 10.1016/j.jcyt.2019.03.587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Patel S, Huang J, Saunders D, Hoq F, Roesch L, Hanley P, Keller M, Simon G, Nixon D, Jones B, Bollard C. HIV-specific T cells can be generated against conserved non-escaped HIV epitopes for use in a phase I clinical trial: Pre-clinical validations and implications for a cure strategy for HIV. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Damen A, Heyenbruch D, Gong N, Maurer K, Grimley M, Nelson A, Davies S, Lutzko C, Zhu X, Bollard C, Hanley P, Leemhuis T. Production of quadrivalent virus-specific t cells utilizing peptide stimulation. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Ulrey R, Albihani S, Cruz C, Bollard C, Hanley P. Efficient expansion of gene-modified t cells in a functionally-closed, semi-automated bioreactor. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
14
|
Burga R, Williams E, Yvon E, Fernandes R, Cruz C, Bollard C. Engineering the TGFβ receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
15
|
Patel S, Huang J, Wright K, Albihani S, Misra A, Zhou P, Jones B, Kimata J, Bollard C, Cruz R. HIV-specific T cells expressing an X5-GPI artificial receptor can suppress HIV replication in vitro—implications for a cure strategy for HIV+ individuals with hematologic malignancies. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
16
|
Huang SH, Ren Y, Macedo A, Patel S, Chan D, Horch E, Truong R, Bollard C, Bosque A, Jones R. BCL-2 inhibitor sensitizes the latent HIV reservoir to elimination by CTLs. J Virus Erad 2017. [DOI: 10.1016/s2055-6640(20)30549-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
18
|
Castillo-Caro P, Wright K, Kontoyiannis D, Bose S, Hazrat Y, Albert N, Bollard C, Rooney C, Cruz C. Developing T cell based immunotherapies for mucormycosis post HSCT. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
19
|
Keller M, Darko S, Hanley P, Hoover J, Roesch L, Lang H, McCormack S, Williams E, Manka C, Barese C, Abraham A, Williams K, Jacobsohn D, Perez-Albuerne E, Davila B, Ransier A, Douek D, Bollard C. Adoptive t cell immunotherapy restores targeted antiviral immunity in immunodeficient patients. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
20
|
Abraham A, Keller M, McLaughlin L, Albihani S, Williams E, Saunders D, Lang H, Roesch L, Hoover J, Barese C, Hanley P, Bollard C. Adoptive transfer of multivirus-specific T cells can rapidly restore virus-specific immunity in patients with sickle cell disease undergoing hematopoietic stem cell transplantation. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
21
|
Yvon E, Burga R, Powell A, Fernandes R, Nguyen T, Abdel-Baki M, Barese C, Cruz C, Bollard C. Cord blood natural killer cells expressing a dominant negative TGF-b receptor: Implications for adoptive immunotherapy. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
22
|
Dave H, Luo M, Blaney J, Shpall E, Bollard C, Hanley P. Rapid manufacture of multi-virus specific T cells targeting BKV, adenovirus, CMV and EBV for recipients of umbilical cord blood transplant. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Patel S, Lam S, Sung J, Cruz R, Goonetilleke N, Xu Y, Kuruc J, Gay C, Jones B, Shpall E, Margolis D, Ambinder R, Bollard C. HIV specific T cells generated from HIV naive adult and cord blood donors target a range of novel viral epitopes—implications for a cure strategy after allogeneic HSCT and CBT. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Patel S, Wright K, Misra A, Zhou P, Kimata J, Bollard C, Cruz R. HIV specific t cells expressing an X5–GPI artificial receptor can suppress hiv replication in vitro— implications for a cure strategy for HIV+ individuals with hematologic malignancies. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
25
|
Burga R, Mejia JC, Cruz C, Bollard C, Fernandes R. Lymphocyte-nanoparticle biohybrids as a combined nanoimmunotherapy for cancer. Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
26
|
Heslop H, Lapteva N, Sharma S, Perna S, Ramos C, Bollard C, Torrano V, Gee A, Rouce R, Brenner M, Rooney C. Rapidly-Generated EBV-Specific T Cells (Ebvst-Cells) to Treat Type 2 Latency Lymphoma. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
Cruz C, Patel S, Sung J, Lam S, Hanley P, Kuruc J, Ambinder R, Margolis D, Bollard C. Ex Vivo Expanded HIV-Specific T Cells From HIV+ Patients and Virus-Naïve Donors are Functionally Active: Implications for a Cure Strategy Post HSCT. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
28
|
Hanley P, Keller M, Martin Manso M, Martinez C, Leung K, Cruz C, Barese C, McCormack S, Luo M, Krance R, Jacobsohn D, Rooney C, Heslop H, Shpall E, Bollard C. A Phase 1 Perspective: Multivirus-Specific T Cells From Both Cord Blood and Bone Marrow Transplant Donors. Cytotherapy 2016. [DOI: 10.1016/j.jcyt.2016.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
29
|
Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 2016; 50 Suppl 2:S55-62. [PMID: 26039209 DOI: 10.1038/bmt.2015.97] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We are entering a very exciting era in umbilical cord blood transplantation (UCBT), where many of the associated formidable challenges may become treatable by ex vivo graft manipulation and/or adoptive immunotherapy utilizing specific cellular products. We envisage the use of double UCBT rather than single UCBT for most patients; this allows for greater ability to treat larger patients as well as to manipulate the graft. Ex vivo expansion and/or fucosylation of one cord will achieve more rapid engraftment, minimize the period of neutropenia and also give certainty that the other cord will provide long-term engraftment/immune reconstitution. The non-expanded (and future dominant) cord could be chosen for characteristics such as better HLA matching to minimize GvHD, or larger cell counts to enable part of the unit to be utilized for the development of specific cellular therapies such as the production of virus-specific T-cells or chimeric-antigen receptor T-cells which are reviewed in this study.
Collapse
Affiliation(s)
- P A Thompson
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - K Rezvani
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - C M Hosing
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - B Oran
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - A L Olson
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - U R Popat
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - A M Alousi
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - N D Shah
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - S Parmar
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - C Bollard
- Center for Cell Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX, USA
| | - P Hanley
- Center for Cell Therapy and Department of Immunology, Baylor College of Medicine, Houston, TX, USA
| | - P Kebriaei
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - L Cooper
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - J Kellner
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - I K McNiece
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| | - E J Shpall
- Department of Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
30
|
Hanley P, Krance R, Brenner M, Leen A, Rooney C, Shpall E, Heslop H, Bollard C. Evaluating multivirus-specific T cells from both cord blood and bone marrow transplant donors: a phase 1 perspective. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Lam S, Cruz C, Garrido Pavon C, Marsh Sung J, Ngo M, Ando J, Kuruc J, Gay C, Rooney C, Margolis D, Bollard C. Proposal for the generation of HIV-specific T cells from art patients. Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
32
|
Ngo M, Ando J, Gottschalk S, Bollard C, Heslop H, Rooney C. An antigen presenting complex for the generation of broad-specificity effector T lymphocytes for the treatment of EBV-associated malignancies. Cytotherapy 2013. [DOI: 10.1016/j.jcyt.2013.01.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Shah N, Ku S, Xing D, Lee D, Cooper L, Tzou B, Decker W, Li S, Robinson S, Yang H, Parmar S, Tung S, Bollard C, Shpall E. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Significant Expansion of Natural Killer Cells With Anti-Myeloma Activity. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, Shah N, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJ. CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. Bone Marrow Transplant 2009; 45:1000-7. [PMID: 19838220 DOI: 10.1038/bmt.2009.289] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Cord blood (CB) is used increasingly in transplant patients lacking sibling or unrelated donors. A major hurdle in the use of CB is its low cell dose, which is largely responsible for an elevated risk of graft failure and a significantly delayed neutrophil and platelet engraftment. As a positive correlation has been shown between the total nucleated cell (TNC) and CD34(+) cell dose transplanted and time to neutrophil and platelet engraftment, strategies to increase these measures are under development. One strategy includes the ex vivo expansion of CB mononuclear cells (MNC) with MSC in a cytokine cocktail. We show that this strategy can be further improved if CD3(+) and/or CD14(+) cells are first depleted from the CB MNC before ex vivo expansion. Ready translation of this depletion strategy to improve ex vivo CB expansion in the clinic is feasible as clinical-grade devices and reagents are available. Ultimately, the aim of improving TNC and CD34(+) transplant doses is to further improve the rate of neutrophil and platelet engraftment in CB recipients.
Collapse
Affiliation(s)
- H Yang
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
de Lima M, McNiece I, McMannis J, Hosing C, Kebraei P, Komanduri K, Worth L, Staba S, Cooper L, Petropolous D, Lee D, Jones R, Nieto Y, Andersson B, Korbling M, Alousi A, Qazilbash M, Popat U, Khouri I, Bollard C, Leen A, Rondon G, Molldrem J, Champlin R, Simmons P, Shpall E. Double Cord Blood Transplantation (CBT) With Ex-Vivo Expansion (EXP) of One Unit Utilizing A Mesenchymal Stromal Cell (MSC) Platform. Biol Blood Marrow Transplant 2009. [DOI: 10.1016/j.bbmt.2008.12.146] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
36
|
Kamble RT, Bollard C, Demmler G, LaSala PR, Carrum G. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant 2007; 40:699-700. [PMID: 17660843 DOI: 10.1038/sj.bmt.1705781] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
37
|
Rieber A, Parmar S, Robinson S, Decker W, Xing D, Komanduri K, Bollard C, McMannis J, Yang H, Berenson R, Bonyhadi M, Shpall E. Optimization of expansion of cord blood T cells with anti-CD3/anti-CD28 coated beads. Biol Blood Marrow Transplant 2006. [DOI: 10.1016/j.bbmt.2005.11.254] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
38
|
Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ, Anderson R, Prentice HG, Brenner MK, Heslop HE. Immunotherapy for Hodgkin's disease. Ann Hematol 2003; 81 Suppl 2:S39-42. [PMID: 12611071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
EBV proteins present in the malignant Hodgkin Reed-Sternberg (HR-S) cells of about 40% of patients with Hodgkin's Disease (HD) provide targets for immunotherapy with virus-specific cytotoxic T lymphocytes (CTL). However, Hodgkin tumors use multiple strategies to avoid CTL, including down-regulation of immunodominant EBV antigens, and secretion of cytokines and chemokines such as TGF-beta, that inhibit the activation of CTL and professional antigen-presenting cells (APC). To be effective against this tumor, CTL must resist some or all of these strategies. Thirteen patients with multiply-relapsed HD received EBV-specific CTL, generated ex vivo using the autologous EBV-transformed B cells (LCL) as stimulator cells. After CTL infusion, EBV-specific immunity increased, virus load decreased, CTL homed to sites of malignancy and persisted for up to ten months. Clinically, CTL produced resolution of B symptoms and mixed tumor responses including one complete remission of residual disease remaining after autologous bone marrow transplant. However, no complete remission of bulky disease was achieved. Although LMP2-specific CTL activity could be detected in some of the infused CTL lines, they were present in low frequency. In pre-clinical studies, LMP1 and LMP2-specific CTL could be produced by stimulating PBMC from patients and normal donors with autologous dendritic cells expressing LMP1 or LMP2 from adenoviral vectors. Further, CTL could be rendered resistant to the devastating effects of TGF-beta by transduction with a retrovirus vector expressing a dominant-negative TGF-beta receptor, while transgenic IL-12 could increase the expression of Th1 and decrease that of Th2 cytokines. Future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies.
Collapse
Affiliation(s)
- C M Rooney
- Centre for Cell and Gene Therapy, Department of Pediatrics, Division of Hematology and Oncology, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Rousseau R, Bollard C, Heslop H. [Contribution of antineoplastic biotherapy in the treatment of leukemia in children]. Arch Pediatr 2002; 9:289-306. [PMID: 11938542 DOI: 10.1016/s0929-693x(01)00767-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Improvements in the chemotherapeutic and transplant regimens have had a significant impact in improving survival rates for pediatric leukemia. However, there are still major problems to address including what options are available for patients with chemoresistant disease and what strategies are available to avoid toxicity associated with highly cytotoxic treatment regimens. Gene and immunotherapy protocols hold great promise. Using gene transfer of a marker gene, a number of biologic issues in the therapy of leukemia have been addressed. For example, by gene marking autologous bone marrow grafts it has been possible to demonstrate that infused marrow contributes to relapse in acute and chronic myeloid leukemias. In the allogeneic transplant setting, genetically modified T-cells have proven valuable for the prophylaxis and treatment of viral diseases and may have an important role in preventing or treating disease relapse. Gene transfer is also being used to modify tumor function, enhance immunogenicity, and confer drug-resistance to normal hematopoietic stem cells. With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of pediatric leukemia in the future.
Collapse
Affiliation(s)
- R Rousseau
- Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
| | | | | |
Collapse
|
40
|
Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther 2000; 11:1465-75. [PMID: 10910143 DOI: 10.1089/10430340050057530] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Heslop
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston 77030-2399, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Blacklock HA, Dewse M, Bollard C, Hudson P, Barnhill D, Jackson S. Blood donation by healthy individuals with haemochromatosis. N Z Med J 2000; 113:77-8. [PMID: 10855583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
AIM To determine how many individuals with haemochromatosis undergoing therapeutic venesections in our department might be eligible for blood donation. METHODS Patients with genetic haemochromatosis were assessed with respect to complications of their disorder, the presence of other medical conditions and their suitability to be blood donors. RESULTS Of 74 patients, 53 have been tested and shown to be homozygous for the Cys282Tyr mutation, and 30 of these (40%) fulfilled criteria for blood donation. This group is having 409 units of blood removed annually or 13-units per individual that is currently discarded. Of these 30 patients, all (100%) were keen to be blood donors. CONCLUSION It is timely to review the policy regarding use of this wasted blood for transfusion.
Collapse
Affiliation(s)
- H A Blacklock
- Department of Haematology, Middlemore Hospital, Auckland.
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
OBJECTIVE To compare urine collection by urethral catheterization with suprapubic aspiration in a neonatal intensive care unit. METHODOLOGY All urine collections were documented, the collection methods attempted recorded and success rates calculated. The incidence of contaminated specimens was determined. The infants ranged in weight from 570 g to 4180 g and in gestation from 24 to 44 weeks. RESULTS Thirty-two out of 65 (49%) suprapubic aspirations were successful. Overall 33/42 (77%) of catheterizations were successful, 12/18 (67%) were successful when following an unsuccessful SPA. No SPA was contaminated compared to 7/22 (22%) of the catheter specimens. Urinary tract infection was present in 4/63 (6.3%) infants. There were no complications following catheterization. CONCLUSIONS Urethral catheterization is a useful and safe alternative to suprapubic aspiration, but suprapubic aspiration remains the method of first choice.
Collapse
Affiliation(s)
- B J Austin
- Department of Paediatrics, National Women's Hospital, Epsom, New Zealand
| | | | | |
Collapse
|
43
|
O'Connor M, Kiely D, Mulvihill M, Winters A, Bollard C, Hamilton A, Corrigan C, Moore E. School nutrition survey. Ir Med J 1993; 86:89-91. [PMID: 8567245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Food we eat has an important influence on health and well-being. Many eating habits are established in childhood. 456 children aged eight to 12 years participated in this survey of food eaten at school. Of all the food items eaten as a snack, 48.6% were categorised as junk. 75.8% of the sandwiches brought to school for lunch were made with white bread. Of the remaining food items brought for lunch 63.5% were of the junk variety. Compared with those who brought a snack or lunch from home, those given money to buy their own were more likely to eat junk (p < 0.01). Food eaten at school reflects approximately one third of a child's daily food intake but health food practises for even a third of food intake may be of a value for health and long term eating habits. Nutritional education with the reinforcement of high nutritional standards in schools could improve the situation.
Collapse
|